Ling Yang

Ling Yang is a Managing Director and Head of China at Carlyle, where she oversees Carlyle’s operations, private equity team, and investment advisory and portfolio activities in China. She also serves as Co-Head of Healthcare for Carlyle in Asia. 

Ms. Yang began her career at Carlyle in 2005 with the firm’s U.S. healthcare buyout team and subsequently joined Carlyle’s Asia buyout team in 2011. Since joining Carlyle Asia, she has led investments into leading healthcare companies in China including ADICON Holdings Limited, Ambiopharm, Microport Scientific Corporation, Hutchmed, Meinian Onehealth, and Shenzhen Salubris Pharmaceuticals. She currently chairs the board of ADICON Holdings Limited and serves as a board member of Ambiopharm and Hutchmed.

Prior to joining Carlyle, Ms. Yang worked at KKR in Asia and in investment banking at Goldman Sachs in the U.S. 

Ms. Yang graduated summa cum laude with a B.A. in Economics and Computer Science from Smith College and received an MBA from Harvard Business School.